251 related articles for article (PubMed ID: 33955591)
1. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
[TBL] [Abstract][Full Text] [Related]
2. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
[TBL] [Abstract][Full Text] [Related]
3. Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study.
Turunen A; Valtola J; Partanen A; Ropponen A; Kuittinen O; Kuitunen H; Vasala K; Ågren L; Penttilä K; Keskinen L; Savolainen ER; Pyörälä M; Kuittinen T; Selander T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
Leuk Lymphoma; 2020 Sep; 61(9):2082-2092. PubMed ID: 32419549
[TBL] [Abstract][Full Text] [Related]
4. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CD34
Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
[TBL] [Abstract][Full Text] [Related]
6. Impact of lenalidomide-based induction therapy on the mobilization of CD34
Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
[TBL] [Abstract][Full Text] [Related]
7. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study.
Turunen A; Partanen A; Valtola J; Ropponen A; Siitonen T; Kuittinen O; Kuitunen H; Putkonen M; Sankelo M; Keskinen L; Savolainen ER; Pyörälä M; Kuittinen T; Silvennoinen R; Penttilä K; Sikiö A; Vasala K; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2020 Jul; 60(7):1519-1528. PubMed ID: 32333404
[TBL] [Abstract][Full Text] [Related]
8. Impact of the number of cryopreserved CD34
Partanen A; Turunen A; Silvennoinen R; Valtola J; Pyörälä M; Siitonen T; Sikiö A; Putkonen M; Sankelo M; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
J Clin Apher; 2023 Feb; 38(1):33-44. PubMed ID: 36239392
[TBL] [Abstract][Full Text] [Related]
9. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Putkonen M; Partanen A; Pyörälä M; Savolainen ER; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
Leuk Lymphoma; 2019 Feb; 60(2):453-461. PubMed ID: 30160591
[TBL] [Abstract][Full Text] [Related]
10. Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma.
Partanen A; Kuittinen O; Turunen A; Valtola J; Pyorala M; Kuitunen H; Vasala K; Kuittinen T; Mantymaa P; Pelkonen J; Jantunen E; Varmavuo V
J Hematol; 2021 Dec; 10(6):246-254. PubMed ID: 35059086
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD34
Partanen A; Turunen A; Valtola J; Pyörälä M; Kuittinen O; Kuitunen H; Vasala K; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e428-e435. PubMed ID: 37684185
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
13. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Hicks C; Wong R; Manoharan A; Kwan YL
Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
[TBL] [Abstract][Full Text] [Related]
14. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
15. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
16. CD34
Turunen AS; Kuittinen O; Kuitunen H; Vasala K; Penttilä K; Harmanen M; Keskinen L; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E; Partanen A
Transfus Med Hemother; 2023 Oct; 50(5):428-437. PubMed ID: 37899989
[TBL] [Abstract][Full Text] [Related]
17. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
Lanza F; Campioni D; Moretti S; Dominici M; Punturieri M; Focarile E; Pauli S; Dabusti M; Tieghi A; Bacilieri M; Scapoli C; De Angeli C; Galluccio L; Castoldi G
Exp Hematol; 2001 Dec; 29(12):1484-93. PubMed ID: 11750108
[TBL] [Abstract][Full Text] [Related]
18. Unfractionated peripheral blood stem cell autografts and CD(34+)-enriched autografts have similar long-term culture initiating capacity in multiple myeloma.
Turhan AG; Bourhis JH; Bonnet ML; Novault S; Bayle C; Bennaceur A; Vainchenker W; Pico JL; Beaujean F
Hematol Cell Ther; 1999 Nov; 41(5):197-204. PubMed ID: 10651119
[TBL] [Abstract][Full Text] [Related]
19. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
Jantunen E; Fruehauf S
Bone Marrow Transplant; 2011 May; 46(5):627-35. PubMed ID: 21217789
[TBL] [Abstract][Full Text] [Related]
20. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
